Functions of Tau protein in human neural cells

Tau蛋白在人类神经细胞中的功能

基本信息

  • 批准号:
    10658624
  • 负责人:
  • 金额:
    $ 26.99万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2023
  • 资助国家:
    美国
  • 起止时间:
    2023-04-15 至 2025-03-31
  • 项目状态:
    未结题

项目摘要

Project Summary/Abstract Tau protein, encoded by the MAPT gene, is a neuronally enriched protein with an established role as a microtubule-binding protein. Abnormal accumulation of tau protein is a neuropathological hallmark of several neurodegenerative diseases, including Alzheimer’s disease (AD) and frontotemporal dementia (FTD). Dominant mutations in the MAPT gene are present in inherited FTD, indicating that tau is causal in neurodegenerative disease. However, whether these mutations lead to loss-of-function, gain-of-function or the acquisition of a novel function is unknown. Furthermore, although there are no mutations in MAPT that cause inherited AD, how alterations in tau function contribute to dysfunction in neural cells and pathological aggregation of tau protein are still incompletely understood. These issues have not been resolved, largely because the functions of the tau protein have not been conclusively determined. While highly expressed in neurons, tau is expressed in other CNS cell types and has been linked to cellular localizations ranging from the nucleolus to the plasma membrane. Furthermore tau-interacting proteins display a range of cellular functions including gene regulation, membrane transport, RNA binding and metabolism and cytoskeletal elements. Together this suggests a role for tau protein in central nervous system cells beyond microtubule stabilization. Many studies have examined the effects of pathological tau, but only a limited number of studies have investigated the cellular functions of wild type, endogenous tau. Examining cellular phenotypes in the absence of tau is one approach to understand its normal function. To date, most studies have studied tau deficiency using rodent models or transformed human cell lines and these studies show various and sometimes conflicting results. In this study, we will use our expertise in human induced pluripotent stem cell technology to study loss of tau function in human neural cultures and cortical organoids. We will use CRISPR/Cas9 to disrupt the human tau reading frame, generating tau-KO cell lines. We will then pursue both unbiased transcriptomic profiling and hypothesis-based experiments examining molecular and physiological consequences in neurons and astrocytes deficient in tau expression. We have generated pilot data indicating a strong up-regulation of pathways involved in neuroimmune function in tau-KO cortical cultures compared to isogenic WT controls and we have validated our findings with shRNAs targeting MAPT. Our proposed experiments will use hiPSC-derived neurons and astrocytes to test cell autonomous and non-cell autonomous responses to tau deficiency. These tau deficiency phenotypes include altered granulostasis and the accumulation of double-stranded RNA, as suggested by our preliminary studies. We will also assess electrophysiological function of tau deficient neurons cultured with wild-type astrocytes and wild-type neurons cultured with tau deficient astrocytes. To our knowledge, there are no reports of tau-KO in hiPSC-derived neural cell types, therefore the data generated by this study has the potential to significantly contribute to understanding the role of tau in the central nervous system.
Project Summary/Abstract Tau protein, encoded by the MAPT gene, is a neuronally enriched protein with an established role as a microtubule-binding protein. Abnormal accumulation of tau protein is a neuropathological hallmark of several neurodegenerative diseases, including Alzheimer’s disease (AD) and frontotemporal dementia (FTD). Dominant mutations in the MAPT gene are present in inherited FTD, indicating that tau is causal in neurodegenerative disease. However, whether these mutations lead to loss-of-function, gain-of-function or the acquisition of a novel function is unknown. Furthermore, although there are no mutations in MAPT that cause inherited AD, how alterations in tau function contribute to dysfunction in neural cells and pathological aggregation of tau protein are still incompletely understood. These issues have not been resolved, largely because the functions of the tau protein have not been conclusively determined. While highly expressed in neurons, tau is expressed in other CNS cell types and has been linked to cellular localizations ranging from the nucleolus to the plasma membrane. Furthermore tau-interacting proteins display a range of cellular functions including gene regulation, membrane transport, RNA binding and metabolism and cytoskeletal elements. Together this suggests a role for tau protein in central nervous system cells beyond microtubule stabilization. Many studies have examined the effects of pathological tau, but only a limited number of studies have investigated the cellular functions of wild type, endogenous tau. Examining cellular phenotypes in the absence of tau is one approach to understand its normal function. To date, most studies have studied tau deficiency using rodent models or transformed human cell lines and these studies show various and sometimes conflicting results. In this study, we will use our expertise in human induced pluripotent stem cell technology to study loss of tau function in human neural cultures and cortical organoids. We will use CRISPR/Cas9 to disrupt the human tau reading frame, generating tau-KO cell lines. We will then pursue both unbiased transcriptomic profiling and hypothesis-based experiments examining molecular and physiological consequences in neurons and astrocytes deficient in tau expression. We have generated pilot data indicating a strong up-regulation of pathways involved in neuroimmune function in tau-KO cortical cultures compared to isogenic WT controls and we have validated our findings with shRNAs targeting MAPT. Our proposed experiments will use hiPSC-derived neurons and astrocytes to test cell autonomous and non-cell autonomous responses to tau deficiency. These tau deficiency phenotypes include altered granulostasis and the accumulation of double-stranded RNA, as suggested by our preliminary studies. We will also assess electrophysiological function of tau deficient neurons cultured with wild-type astrocytes and wild-type neurons cultured with tau deficient astrocytes. To our knowledge, there are no reports of tau-KO in hiPSC-derived neural cell types, therefore the data generated by this study has the potential to significantly contribute to understanding the role of tau in the central nervous system.

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Jessica Elaine Young其他文献

Jessica Elaine Young的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Jessica Elaine Young', 18)}}的其他基金

Engineering Human Brain Neurovascular Niche for Modeling Brain Diseases
工程人脑神经血管生态位以模拟脑疾病
  • 批准号:
    10478162
  • 财政年份:
    2021
  • 资助金额:
    $ 26.99万
  • 项目类别:
Engineering Human Brain Neurovascular Niche for Modeling Brain Diseases
工程人脑神经血管生态位以模拟脑疾病
  • 批准号:
    10303483
  • 财政年份:
    2021
  • 资助金额:
    $ 26.99万
  • 项目类别:
Role of HDAC2 as a modulator of aging and Alzheimer's disease phenotypes in stem-cell derived neurons
HDAC2 作为干细胞衍生神经元衰老和阿尔茨海默氏病表型调节剂的作用
  • 批准号:
    10377380
  • 财政年份:
    2019
  • 资助金额:
    $ 26.99万
  • 项目类别:
Role of HDAC2 as a modulator of aging and Alzheimer's disease phenotypes in stem-cell derived neurons
HDAC2 作为干细胞衍生神经元衰老和阿尔茨海默氏病表型调节剂的作用
  • 批准号:
    10620637
  • 财政年份:
    2019
  • 资助金额:
    $ 26.99万
  • 项目类别:
Probing the role of SORL1 and endosomal network genetic variation on Alzheimer's disease phenotypes in human neurons.
探讨 SORL1 和内体网络遗传变异对人类神经元阿尔茨海默病表型的作用。
  • 批准号:
    10433931
  • 财政年份:
    2018
  • 资助金额:
    $ 26.99万
  • 项目类别:
Probing the role of SORL1 and endosomal network genetic variation on Alzheimer's disease phenotypes in human neurons.
探讨 SORL1 和内体网络遗传变异对人类神经元阿尔茨海默病表型的作用。
  • 批准号:
    9982742
  • 财政年份:
    2018
  • 资助金额:
    $ 26.99万
  • 项目类别:
Probing the role of SORL1 and endosomal network genetic variation on Alzheimer's disease phenotypes in human neurons.
探讨 SORL1 和内体网络遗传变异对人类神经元阿尔茨海默病表型的作用。
  • 批准号:
    10221575
  • 财政年份:
    2018
  • 资助金额:
    $ 26.99万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了